18F-FDG PET/CT疗效评估在4期神经母细胞瘤患儿中的预后作用
回顾性分析39例初诊4期神经母细胞瘤患儿,基线与化疗后均行18F-FDG PET/CT,评估代谢参数与长期生存的关联。中位随访56个月,化疗后PET完全缓解者5年总生存优于未完全缓解者(73.6% vs 39.0%,p=0.044);SUVe>1.2是无事件生存和总生存的独立预测因子。
要点
- 化疗后PET完全缓解(无高于周围本底的残留FDG摄取)者5年总生存73.6% vs 39.0%(p=0.044)。
- SUVe>1.2独立预测更差无事件生存(HR 3.479)与总生存(HR 6.948)。
- SUVb>6.9预测更差无事件生存(HR 2.889),5年无事件生存12.5% vs 59.3%。
核心结论
- 18F-FDG PET/CT可能有助于评估4期神经母细胞瘤患儿的治疗反应,化疗后PET/CT具有预后意义。
研究设计与样本
- 回顾性分析39例连续纳入的新初诊4期神经母细胞瘤患儿,基线与化疗后均行18F-FDG PET/CT,评估代谢参数与长期生存的关联。
诊断标准与关键数值
- 化疗后PET完全缓解定义为无残留18F-FDG摄取高于周围本底,22例达到者5年总生存73.6% vs 39.0%(p=0.044)。
- SUVb>6.9者5年无事件生存12.5% vs 59.3%(p=0.005)。
- SUVe>1.2者5年无事件生存18.8% vs 41.7%(p=0.041),5年总生存33.9% vs 75.0%(p=0.018)。
- 多因素分析:SUVe>1.2为无事件生存独立预测因子(HR 3.479,95%CI 1.381-8.761,p=0.008)和总生存独立预测因子(HR 6.948,95%CI 1.663-29.025,p=0.008);SUVb>6.9为无事件生存预测因子(HR 2.889,95%CI 1.064-7.842,p=0.037)。
- 11例同时SUVb>6.9且SUVe>1.2的患儿均在诊断后2年内出现疾病进展或复发。
临床应用与阅片要点
- 化疗后18F-FDG PET/CT的代谢反应可用于4期神经母细胞瘤患儿的预后评估。
- 对于间碘苄胍(MIBG)非摄取或持续摄取病灶的病例,18F-FDG PET/CT可能作为反应评估的替代影像方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the association between metabolic response on 18F-FDG PET/CT and long-term survival in children with neuroblastoma (NB).
METHODS: A total of 39 consecutive children with newly diagnosed stage 4 NB undergoing both 18F-FDG PET/CT imaging at baseline and after chemotherapy were retrospectively analyzed. The associations between metabolic parameters, including SUVmax of the lesion with the most intense 18F-FDG uptake at baseline (SUVb), after chemotherapy (SUVe), and the percentage change between SUVb and SUVe, and long-term survival were evaluated.
RESULTS: With a median follow-up of 56 months, 22 patients who had achieved complete resolution on PET (no residual 18F-FDG uptake higher than the surrounding backgrounds) after chemotherapy had superior 5-year overall survival (OS) (73.6% vs. 39.0%, p = 0.044). SUVb > 6.9 indicated significantly poorer 5-year event-free survival (EFS) (12.5% vs. 59.3%, p = 0.005), as did SUVe > 1.2 (18.8% vs. 41.7%, p = 0.041). Children with SUVe > 1.2 had shorter 5-year OS (33.9% vs. 75.0%, p = 0.018). Multivariate analysis identified SUVe > 1.2 as an independent predictor for both EFS [hazard ratio (HR), 3.479, 95% CI, 1.381-8.761, p = 0.008] and OS (HR, 6.948, 95% CI, 1.663-29.025, p = 0.008), while SUVb > 6.9 was a predictor for EFS (HR, 2.889, 95% CI, 1.064-7.842, p = 0.037). Among 11 children with both SUVb > 6.9 and SUVe > 1.2, all experienced disease progression or relapse within 2 years since diagnosis.
CONCLUSION: 18F-FDG PET/CT could be of useful to evaluate treatment response in children with stage 4 NB.
CLINICAL RELEVANCE STATEMENT: 18F-FDG PET/CT after chemotherapy exhibits prognostic significance in neuroblastoma and holds potential as an alternative imaging modality for response evaluation, especially in cases with metaiodobenzylguanidine-nonavid or persistent avid disease.
KEY POINTS: The prognostic value of chemotherapy response on 18F-FDG PET/CT in advanced neuroblastoma is unknown. Higher 18F-FDG uptake after chemotherapy was associated with worse long-term event-free survival and overall survival. 18F-FDG PET/CT after chemotherapy holds prognostic significance in children with stage 4 neuroblastoma.
引用
- Lu X, Li C, Wang S, et al. The prognostic role of 18F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma. Eur Radiol. 2024. PMID: 38758254. doi:10.1007/s00330-024-10781-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。